Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTL-CEBPA plus Atezolizumab and Bevacizumab in Advanced HCC
NCT05097911Phase 1Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Aug 2021
- Primary completion
- Apr 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of MTL-CEBPA in hepatocellular carcinoma (HCC), sponsored by National University Hospital. Started Aug 2021; status: active, not recruiting.
02
Drugs
MTL-CEBPA
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05097911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097911.